Quarterly ResultMay 7, 2026, 09:13 AM
Delcath Systems Q1 Net Loss $1.07M; Revenue Up 26.3%
AI Summary
Delcath Systems reported a net loss of $(1.07) million for the first quarter of 2026, a shift from a net income of $1.07 million in the prior year period. Despite the loss, product revenue increased by 26.3% to $25.0 million. The company continues to advance its clinical development programs for HEPZATO, with Phase 2 trials for metastatic colorectal cancer and metastatic breast cancer progressing, and also repurchased $3.0 million of common stock during the quarter.
Key Highlights
- Net loss was $(1.07) million for Q1 2026, compared to net income of $1.07 million for Q1 2025.
- Product revenue increased 26.3% to $25.0 million for Q1 2026 from $19.8 million in Q1 2025.
- Gross profit rose to $21.3 million for Q1 2026, up from $16.9 million in Q1 2025.
- Operating loss was $(1.64) million for Q1 2026, compared to operating income of $0.64 million in Q1 2025.
- Basic loss per common share was $(0.03) for Q1 2026, versus basic income per share of $0.03 for Q1 2025.
- Cash and cash equivalents totaled $41.3 million as of March 31, 2026.
- The company repurchased $3.0 million of common stock in Q1 2026, with $16.0 million remaining under the program.
- Phase 2 clinical trials for HEPZATO in metastatic colorectal cancer and metastatic breast cancer are underway.
Price Impact
More from DCTH